Pharmacy and Poisons Board of Hong Kong

香港藥劑業及毒藥管理局

Annual Report

2020

年報

Contents
目錄

Message from the Chairman
主席獻辭

In the midst of the global pandemic of COVID-19, 2020 has been a challenging and unforgettable year. Despite the difficulties, the Pharmacy and Poisons Board ("the Board") continued to strive in our best for better health protection and quality healthcare service.

In order to combat the COVID-19 pandemic, technological development in the medical and pharmaceutical fields, including development of COVID-19 vaccines and treatment, is evolving at an exceptionally high speed. In this connection, the Board has robustly conducted evaluation and granted approval for clinical trials of the investigational COVID-19 drug "Remdesivir" in 2020 in an expeditious manner. In addition, the Board has formulated a conditional registration framework to resiliently address the local unmet and urgent medical needs during the COVID-19 public health emergency, with continuous monitoring of the safety and efficacy of the products.

Concerning regulation of advanced therapy products ("ATPs"), the Board is pleased to note that the Pharmacy and Poisons (Amendment) Bill 2019 ("the Bill") was passed by the Legislative Council on 17 July 2020 and published in the Gazette as the Pharmacy and Poisons (Amendment) Ordinance 2020 ("the Amendment Ordinance") on 24 July 2020. In view of the high risks associated with the rapid scientific advancement of ATPs, the Amendment Ordinance aims at introducing a clear regulatory framework on clinical research and therapeutic use of ATPs in order to safeguard public health and facilitate their development. The Amendment Ordinance seeks to update the existing legislation to regulate the ATPs by setting out a specific subset of pharmaceutical products under the Pharmacy and Poisons Ordinance (Cap. 138, Laws of Hong Kong) ("the Ordinance") so that the regulatory requirements for pharmaceutical products under the Ordinance and other relevant ordinances would apply to ATPs. Due to the high-risk and complex nature of ATPs, all facilities which manufacture ATPs should obtain a licence. In addition, considering the special nature of ATPs, the Amendment Ordinance provides for requirements on labelling and record keeping specific to ATPs in order to enhance traceability of the products. The provisions of the Amendment Ordinance will come into operation on 1 August 2021.

To cater for the genuine need in keeping actual sales pack of ATPs for registration purpose by taking into account the scarcity of materials for certain biological products, the Amendment Ordinance also updates the registration requirement by only requiring submission of prototypes of sales packs and proposed wordings of the label instead of representative specimen sales packs of pharmaceutical products or samples of substance. This is a trade facilitating measure for applications for registration of pharmaceutical products without compromising the rigorous requirements in monitoring the safety, quality and efficacy of the products.

With the aim to ensure that registered authorized persons ("APs") of licensed manufacturers are keeping up-to-date knowledge and experiences for maintaining quality profession practice in the manufacture of pharmaceutical products, the requirement for continuing professional development ("CPD") has been implemented since 2020. Since then, an AP must provide evidence that he or she

二零二零年是難忘的一年，因2019冠狀病毒病(下稱「冠狀病毒病」)肆虐全球，帶來重重挑戰。雖然挑戰不斷，但藥劑業及毒藥管理局(下稱「本局」)一如以往，竭盡所能保障公眾健康，矢志提供優質的醫療服務。

為應付冠狀病毒病大流行，醫療及製藥技術包括新冠疫苗及相關治療方法正急速發展。年內，本局經全面評估之後，從速批准對用於此病的新藥瑞德西韋(Remdesivir)進行臨牀測試。因應冠狀病毒病導致的公共衞生緊急事態影響，本局制定了有條件註冊機制以適切地處理及滿足本地緊急的醫療需求，並持續監察有關產品的安全及效能。

在先進療法製品的規管方面，本局欣悉《2019年藥劑業及毒藥(修訂)條例草案》於二零二零年七月十七日獲立法會通過，並於二零二零年七月二十四日刊憲，為《2020年藥劑業及毒藥(修訂)條例》(下稱「《修訂條例》」)。鑑於先進療法製品的科學發展迅速及屬高風險，政府訂立了《修訂條例》，就先進療法製品的臨牀研究及治療應用引入清晰的規管框架，以保障公眾健康及促進先進療法製品的發展。《修訂條例》旨在修訂現行法例，訂明先進療法製品為香港法例第138章《藥劑業及毒藥條例》(下稱「《條例》」)下藥劑製品的一個特定分類。經此修訂，《條例》及其他相關條例對藥劑製品的規管要求亦適用於先進療法製品，從而令有關製品受到規管。鑑於先進療法製品具高風險並其性質複雜，因此，所有製造先進療法製品的設施均須領取牌照。此外，考慮到先進療法製品的獨特性，《修訂條例》就這類製品的標籤及紀錄備存作出規定，務使該類製品更易於追查。《修訂條例》於二零二一年八月一日起實施。

監管當局有真正需要保存先進療法製品的實際銷售包作註冊用途，但由於某些生物製品的材料稀有，《修訂條例》更新有關註冊規定，訂明在申請藥物註冊時只需提交銷售包的原型及擬用的標籤字句，以符合原本提供藥劑製品的銷售包典型樣品或物質的樣本的要求。此舉既便利業界，同時又不會影響對藥劑製品安全、質素和效能的嚴格規定。

為確保持牌製造商的註冊獲授權人具備最新知識及累積相當經驗，能夠在製造藥劑製品時維持其專業的執業質素，本局自二零二零年起訂立了持續專業進修的規定。獲授權人如欲續期註冊，必須在二零二一年一月及此後每年提交證據，證明自己於

has undertaken the minimum number of CPD hours (20 hours for pharmaceutical manufacturers or 7 hours for secondary packaging manufacturers) at courses, seminars or other forms of approved training of a current year for the renewal of their registration in January 2021 and thereafter annually.

All along, the Board has supported and implemented various measures to tackle the global public health concern of antimicrobial resistance ("AMR"). With reference to the "Hong Kong Strategy and Action Plan on Antimicrobial Resistance (2017 - 2022)" and with the enhanced measures and support from the pharmacy profession and the pharmacy trade, the overall supply of antimicrobials to authorized sellers of poisons decreased from 18.4% in 2016 to 7.5% in 2019. Besides, the Board took the initiative to strengthen the control of certain antimicrobials which were used to be over-the-counter medicines by re-classifying them as prescription drugs. These antimicrobials include nifuratel, nifuroxazide, nitrofural, nitrofurantoin and nitroxoline, the new sales restrictions of which have taken effect on 18 October 2020. Furthermore, the Board also reclassified metronidazole from pharmacy-only medicine to prescription medicine with effect from 14 February 2021.

For better protection of public health, the Board has continuously monitored and reviewed the safety of medicines in the market and made reference to the international regulatory practice. In this connection, the sales restrictions of pharmaceutical products containing piracetam, which is used for treatment of myoclonus of cortical origin and memory problems, and pentoxifylline, which is used for treatment of peripheral vascular disorders, have been strengthened by re-classifying them as prescription drugs with effect from 18 October 2020 and 13 December 2020 respectively. Moreover, for safe and proper use of skin antiseptic products, the Board endorsed in September 2020 to tighten the sales control of skin antiseptic products containing benzalkonium salts, benzethonium salts, cetrimide, hydrogen peroxide, or iodine/povidone iodine for human or animal use as pharmaceutical products unless otherwise stated, or except for general toiletry or cosmetic products containing these antiseptic substances as preservatives, or intended for general cleansing or sanitary use, such as hand wash, body wash, cleanser and shampoo. The tightened control will come into effect on 11 June 2022.

While recollecting the accomplishments of the Board in the past year, I would like to take the opportunity to thank all Members of the Board and various committees of the Board for their insight and contribution. I am also grateful for the support of the pharmacy profession and trade. It is my sincere wish that the pharmacy community will uphold the professional standard and achieve further in providing quality healthcare services.

Dr CHAN Hon-yee, Constance, JP
Chairman
Pharmacy and Poisons Board

該年已透過修讀課程、參加研討會、或接受其他核准的培訓形式，完成最低持續專業進修時數(藥物製造商20小時、外包裝製造商7小時)。

為應對抗菌素耐藥性此一全球關注的公共衞生議題，本局一直支持及推行了多項相關措施。參照《香港抗菌素耐藥性策略及行動計劃(2017-2022)》所訂目標，並受惠於有關的加強措施以及藥劑師專業和藥劑業界的支持，獲授權毒藥銷售商供應的抗菌素佔整體供應的比例由二零一六年的18.4%下降至二零一九年的7.5%。此外，為加強對抗菌素的管制，本局主動將若干原屬非處方藥物的抗菌素改列為處方藥物，當中包括硝呋太爾、硝呋齊特、呋喃西林、呋喃妥因及硝羥喹啉。新訂的銷售管制已於二零二零年十月十八日生效。另外，從二零二一年二月十四日開始，甲硝唑從原屬藥劑師監督下在藥房售賣的藥物改列為處方藥物。

為加強保障公眾健康，本局參照國際規管慣例，持續監察及檢視市場上的藥物安全。本局先後把含有吡拉西坦(用於治療皮質性陣發性抽搐及記憶問題)及己酮可可鹼(用於治療末梢血管疾病)的藥劑製品改列為處方藥物，於二零二零年十月十八日及二零二零年十二月十三日起生效，藉此加強對相關藥劑製品的銷售管制。此外，為確保市民安全及正確地使用皮膚消毒產品，本局於二零二零年九月同意收緊相關產品的銷售規管，除非另有訂明，將含有苯甲烴銨的鹽類、苯乙銨的鹽類、西三溴銨、雙氧水或碘/聚維酮碘液並用於人或動物皮膚的消毒產品歸類為藥劑製品，而一般清潔衞生用品或化粧品如含有殺菌劑作為防腐劑或用作一般清潔或衞生用途(例如洗手液、沐浴露、清潔劑和洗髮水)則不屬藥劑製品。收緊銷售規管的措施將於二零二二年六月十一日生效。

本局在年內取得上述成果，實有賴本局及屬下各委員會的成員建言獻策，本人謹此致謝。藥劑專業人員及藥劑業對本局工作鼎力支持，本人謹致謝忱。最後，本人衷心希望藥劑業界繼往開來，發揮專業精神，提供更優質的醫療服務。

藥劑業及毒藥管理局主席
陳漢儀醫生

Introduction
引言

This annual report covers the calendar year 2020. Through this report, the Pharmacy and Poisons Board ("the Board") aims to keep all registered pharmacists and interested parties in the pharmacy profession posted on the functions and work of the Board during the year. A brief summary of the work of the Pharmacy and Poisons Appeal Tribunal ("the Appeal Tribunal") established under section 30 of the Pharmacy and Poisons Ordinance is also included.

In order to provide readers with a quick reference, the description of the functions of the Board, its committees and the Appeal Tribunal has been simplified. Readers interested in more specific details of the statutory functions of these bodies should refer to the relevant provisions under the Pharmacy and Poisons Ordinance and its subsidiary legislation.

這份年報載錄藥劑業及毒藥管理局(「管理局」)在二零二零年的工作。管理局希望透過這份年報，使所有註冊藥劑師以及藥劑業有關人士及團體了解管理局的職能及在這年內的工作；同時亦扼要介紹根據《藥劑業及毒藥條例》第30條成立的藥劑業及毒藥上訴審裁處(「上訴審裁處」)的工作。

為使讀者可以更容易掌握有關內容，年報內對管理局及其轄下的委員會和上訴審裁處的職能的描述以精簡為旨。讀者如希望對這些組織的法定職能有更深入的認識，請查閱《藥劑業及毒藥條例》及其附屬法例的有關條文。

All inquiries with regard to this report or to the Board in general can be addressed to:

The Pharmacy and Poisons Board Secretariat
1/F, Shun Feng International Centre
182 Queen's Road East
Wanchai, Hong Kong

Facsimile: (852) 2527 2277
Telephone: (852) 2527 8418
E-mail address : ppb@dh.gov.hk
Website: www.ppbhk.org.hk

所有有關本年報或管理局的查詢，請聯絡：

香港灣仔皇后大道東182號
順豐國際中心一樓
藥劑業及毒藥管理局秘書處

圖文傳真: (852) 2527 2277
電話　　: (852) 2527 8418
電郵地址: ppb@dh.gov.hk
網址　　: www.ppbhk.org.hk

Membership and Functions of the Board
管理局的成員及職能

Dr CHAN Hon-yee, Constance, JP (Chairman)
陳漢儀醫生，JP (主席)

Dr SIN Wai-mei, Della, JP
單慧媚博士，JP

Mr CHAN Ling-fung, Frank
陳凌峯先生

Dr CHIU Pui-yin, Amy, JP
趙佩燕醫生，JP

Mr WONG Wai-hung, Geoffrey
(Legal Adviser)
黃惠鴻先生(法律顧問)

Professor WONG Chi-kei, Ian
黃志基教授

Professor ZUO Zhong, Joan
左中教授

Mr SUNG Ming-tat, Dick
沈明達先生

Ms TAM Hi
譚起女士

Mr YAU Fuk-loi, Rico
邱福來先生

Dr SO Yui-chi
蘇睿智醫生

1. Membership

Members of the Board are appointed by the Chief Executive. Each term is for a period of not more than three years. Members may be re-appointed. The current membership is as follows:

(a) the Director of Health (Chairman);
(b) the Government Chemist;
(c) the Assistant Director of Health in the Drug Office of the Department of Health;

} ex officio members

(d) a medical officer in the Department of Health;
(e) a legal adviser;
(f) a full-time teaching staff of pharmacology of The University of Hong Kong;
(g) a full-time teaching staff of pharmacology of The Chinese University of Hong Kong;
(h) three registered pharmacists (not being public officers) nominated by the Pharmaceutical Society of Hong Kong; and
(i) a registered medical practitioner (not being a public officer) nominated by the Hong Kong Medical Association.

The membership of the Board as at 31 December 2020 was as follows:

(a) Dr CHAN Hon-yee, Constance, JP (Chairman)
(b) Dr SIN Wai-mei, Della, JP
(c) Mr CHAN Ling-fung, Frank
(d) Dr CHIU Pui-yin, Amy, JP
(e) Mr WONG Wai-hung, Geoffrey (Legal Adviser)
(f) Professor WONG Chi-kei, Ian
(g) Professor ZUO Zhong, Joan
(h) Mr SUNG Ming-tat, Dick
Ms TAM Hi
Mr YAU Fuk-loi, Rico
(i) Dr SO Yui-chi

Secretary
Miss WONG So-san, Suzanne

1. 成員

管理局的成員由行政長官委任，每屆任期不多於三年，可以再獲委任。現任成員包括：

(a) 衞生署署長（主席）；
(b) 政府化驗師；
(c) 衞生署藥物辦公室的衞生署助理署長；

} 當然成員

(d) 一名衞生署醫生；
(e) 一名法律顧問；
(f) 一名香港大學藥理學全職教員；
(g) 一名香港中文大學藥理學全職教員；
(h) 三名經香港藥學會提名的註冊藥劑師（非公職人員）；及
(i) 一名經香港醫學會提名的註冊醫生(非公職人員)。

在二零二零年十二月三十一日，管理局的成員計有：

(a) 陳漢儀醫生，JP(主席)
(b) 單慧媚博士，JP
(c) 陳凌峯先生
(d) 趙佩燕醫生，JP
(e) 黃惠鴻先生（法律顧問）
(f) 黃志基教授
(g) 左中教授
(h) 沈明達先生
譚起女士
邱福來先生
(i) 蘇睿智醫生

秘書
黃素珊女士

2. Functions

The Board is established under section 3 of the Pharmacy and Poisons Ordinance to carry out the following functions in accordance with the provisions of the same Ordinance and its subsidiary legislation:

(a) registration of pharmacists, including the prescription of training required for registration, the organization of registration examinations and the issue of certificates of registration and annual practising certificates;

(b) discipline of pharmacists, through inquiry into their conduct by Disciplinary Committees appointed for the purpose;

(c) licensing and regulatory control of retail traders of pharmaceutical products (authorized sellers of poisons and listed sellers of poisons), conducting inspections and test purchases and initiating prosecution of offences and, for authorized sellers of poisons, inquiring into their conduct by Disciplinary Committees appointed for the purpose;

(d) licensing and regulatory control of wholesale dealers and manufacturers of pharmaceutical products;

(e) regulatory control of the selling, purchasing, compounding and dispensing of pharmaceutical products; and

(f) registration and classification of pharmaceutical products.

The Board is assisted by seven committees. They meet regularly to consider and decide on policies and actions in relation to the carrying out of the above functions. The decisions of the Board and its committees are carried out jointly by the Secretariat of the Board and the Drug Office of the Department of Health.

2. 職能

管理局根據《藥劑業及毒藥條例》第3條成立，執行該條例及其附屬法例規定的下述職能：

(a) 處理藥劑師註冊事宜，包括訂明註冊所須的訓練、主辦註冊考試、簽發註冊證明書及週年執業證明書等；

(b) 委出紀律委員會，調查藥劑師的行為操守，並懲處被裁定行為不當的藥劑師；

(c) 規管及簽發藥劑製品零售商(獲授權毒藥銷售商及列載毒藥銷售商)牌照。有關工作包括進行巡查及試買行動、提出檢控及委出紀律委員會調查獲授權毒藥銷售商的經營手法等；

(d) 規管及簽發藥劑製品批發商和製造商牌照；

(e) 規管藥劑製品的銷售、購買、合成和配發事宜；及

(f) 處理藥劑製品的註冊和分類事宜。

管理局轄下設有七個委員會。這些委員會定期舉行會議，就執行上述職能審議和制定政策及行動計劃。管理局及委員會的決定則由管理局秘書處及衞生署藥物辦公室執行。

Membership and Functions of the Committees
管理局委員會的成員及職能

To assist the Board in performing its functions, the following seven committees are established under various provisions of the Pharmacy and Poisons Ordinance:

管理局根據《藥劑業及毒藥條例》內相關的條文成立了下述七個委員會，協助管理局執行職能：

(1) Examination Committee

(i) Membership as at 31 December 2020

Professor WONG Chi-kei, Ian (Chairman)
Dr SIN Wai-mei, Della, JP
Mr CHAN Ling-fung, Frank
Dr LEE Pui-man, Jeff
Ms CHU Kwok-pui, Jody
Mr LAM Fung-shing, Edwin
Dr LAM Tai-ning, Teddy
Professor NG Kwok-wai, Enders
Ms TANG Suk-man, Alice (Secretary)

(ii) Functions

The Examination Committee is established under section 8(3) of the Pharmacy and Poisons Ordinance to:

(a) advise the Board on matters regarding the registration of pharmacists and the training requirements and the examinations for registration;
(b) draw up and review the syllabuses of the registration examinations;
(c) appoint panels to assist in setting question papers and marking answer scripts for the registration examinations;
(d) oversee the setting and marking of examination papers;
(e) prepare and conduct the registration examinations;
(f) review the results of registration examinations and make recommendations regarding applicants' eligibility for registration to the Board for consideration;
(g) consider complaints and unusual circumstances arising from applications for registration or examinations, and make recommendations to the Board for consideration; and
(h) keep under review the standard of the registration examinations.

(1) 考試委員會

(i) 截至二零二零年十二月三十一日的成員名單

黃志基教授 (主席)
單慧媚博士，JP
陳凌峯先生
李培文醫生
朱幗珮女士
林豐盛先生
林泰寧博士
吳國偉教授
鄧淑雯女士 (秘書)

(ii) 職能

考試委員會根據《藥劑業及毒藥條例》第8(3)條成立，負責：

(a) 就有關藥劑師註冊、註冊的訓練要求和考試的事宜向管理局提供意見；
(b) 制定及檢討註冊考試的範圍；
(c) 委聘小組設定註冊試題及評閱試卷；
(d) 監督試卷設定及評卷工作；
(e) 籌備及主辦註冊考試；
(f) 覆核註冊考試的成績，並向管理局就申請人的註冊資格提交建議；
(g) 調查註冊或考試申請的投訴及異常情況，並提交建議供管理局考慮；及
(h) 檢討註冊考試的水平。

(2) Pharmacy and Poisons (Listed Sellers of Poisons) Committee

(i) Membership as at 31 December 2020

Mr CHAN Ling-fung, Frank (Chairman)
Ms AU YEUNG Kar-wai, Terese
Ms LEUNG Chau-yung, Catherine
Mr MUI Cheuk-nang, Kenny
Mr TING Wing-fai
Mr TSE Kwok-keung
Mr YAU Fook-wing, Edward William
Mr LEE Hi-fung, Lees (Secretary)

(ii) Functions

The Pharmacy and Poisons (Listed Sellers of Poisons) Committee is established to consider and approve applications for listed sellers of poisons under regulation 24A of the Pharmacy and Poisons Regulations.

(2) 藥劑業及毒藥(列載毒藥銷售商)委員會

(i) 截至二零二零年十二月三十一日的成員名單

陳凌峯先生 (主席)
歐陽嘉慧女士
梁秋容女士
梅卓能先生
丁志輝先生
謝國強先生
邱福榮先生
李浠鋒先生 (秘書)

(ii) 職能

藥劑業及毒藥(列載毒藥銷售商)委員會負責審批根據《藥劑業及毒藥規例》第24A條提出的列載毒藥銷售商牌照申請。

(3) Pharmacy and Poisons (Wholesale Licences) Committee

(i) Membership as at 31 December 2020

Mr CHAN Ling-fung, Frank (Chairman)
Mr CHENG Kit-man, MH
Mr CHEUNG Yiu-kwong, Alex
Mr CHIU Kwok-leung, Philip
Mr NG Wing-lik
Mr WONG Chi-yin, Andrew
Ms TSE Po-yiu, Blouie (Secretary)

(3) 藥劑業及毒藥(批發牌照)委員會

(i) 截至二零二零年十二月三十一日的成員名單

陳凌峯先生 (主席)
鄭結文先生，MH
張耀光先生
趙國亮先生
吳永力先生
黃志賢先生
謝寶瑤女士 (秘書)

(ii) Functions

In accordance with regulation 26 of the Pharmacy and Poisons Regulations, the Pharmacy and Poisons (Wholesale Licences) Committee is established to:

(a) consider and approve applications for wholesale dealer licence, subject to any conditions it thinks fit to impose; and

(b) revoke a wholesale dealer licence, suspend a wholesale dealer licence for a specified period, issue warning letter(s) to the licensed wholesale dealer or vary a condition of the wholesale dealer licence in the circumstances specified in regulation 26 of the Pharmacy and Poisons Regulations.

(ii) 職能

藥劑業及毒藥(批發牌照)委員會根據《藥劑業及毒藥規例》第26條，執行下列職能：

(a) 在委員會認為適宜施加的條件的規限下，審議及批准批發商牌照的申請；及

(b) 在《藥劑業及毒藥規例》第26條指明的情況下，撤銷批發商牌照、在訂明期間內暫時吊銷批發商牌照、向有關持牌批發商發出警告信或更改施加於批發商牌照的牌照條件。

(4) Pharmacy and Poisons (Manufacturers Licensing) Committee

(i) Membership as at 31 December 2020

Mr CHAN Ling-fung, Frank (Chairman)
Dr CHENG Chi-chung, Vincent
Dr CHEUNG Yan-ting, Kara
Dr CHOW Shing-fung, Aviva
Mr LEE Foo-wing
Professor LEE Wai-yip, Thomas
Professor LEUNG Kam-tong
Dr MAK Yin-fong
Mr TSE Kin-on, Andrew
Mr YEUNG Yee-fai, Raphael (Secretary)

(ii) Functions

The Pharmacy and Poisons (Manufacturers Licensing) Committee is established to carry out the following functions in accordance with the Pharmacy and Poisons Regulations:

(a) consider and approve applications for licence to manufacture pharmaceutical products, subject to any conditions it thinks fit to impose;

(4) 藥劑業及毒藥(製造商牌照)委員會

(i) 截至二零二零年十二月三十一日的成員名單

陳凌峯先生 (主席)
鄭智聰醫生
張欣庭博士
周聖峰博士
李富榮先生
李偉業教授
梁錦堂教授
麥燕芳博士
謝建安先生
楊義輝先生 (秘書)

(ii) 職能

藥劑業及毒藥(製造商牌照)委員會根據《藥劑業及毒藥規例》，執行下列職能：

(a) 在委員會認為適宜施加的條件的規限下，審議及批准藥劑製品製造牌照的申請；

(b) revoke a licence to manufacture pharmaceutical products, suspend a licence to manufacture pharmaceutical products for a specified period, issue warning letter(s) to the licensed manufacturer or vary a condition of the licence to manufacture pharmaceutical products in the circumstances specified in regulation 29 of the Pharmacy and Poisons Regulations;

(c) consider and approve applications for registration as authorized person or renewal of registration as authorized person, subject to any conditions it thinks fit to impose; and

(d) cancel the registration as authorized person, suspend the registration as authorized person for a specified period, issue warning letter(s) to the registered authorized person or vary a condition of the registration as authorized person in the circumstances specified in regulation 30F of the Pharmacy and Poisons Regulations.

(b) 在《藥劑業及毒藥規例》第29條指明的情況下，撤銷藥劑製品製造牌照或在指明期間內暫時吊銷藥劑製品製造牌照、向有關持牌製造商發出警告信或更改施加於藥劑製品製造牌照的牌照條件；

(c) 在委員會認為適宜施加的條件的規限下，審議及批准註冊為獲授權人的註冊申請或續期申請；及

(d) 在《藥劑業及毒藥規例》第30F條指明的情況下，取消獲授權人的註冊或在指明的期間內暫時吊銷獲授權人的註冊、向有關已註冊為獲授權人發出警告信或更改註冊為獲授權人所施加的註冊條件。

(5) Pharmacy and Poisons (Registration of Pharmaceutical Products and Substances: Certification of Clinical Trial/Medicinal Test) Committee

(i) Membership as at 31 December 2020

Mr CHAN Ling-fung, Frank (Chairman)
Professor CHIM Chor-sang
Dr HO Chin-ho, Kenny
Dr HO King-man
Professor LOONG Ho-fung, Herbert
Dr NG Fook-hong
Professor TO Kin-wah, Kenneth
Dr TO Kwong-yuk
Mr WONG Yik-cheong, Anthony
Mr YIM Tsz-kok, Michael (Secretary)

(5) 藥劑業及毒藥（藥劑製品及物質註冊：臨牀試驗及藥物測試證明書）委員會

(i) 截至二零二零年十二月三十一日的成員名單

陳凌峯先生 (主席)
詹楚生教授
何展豪獸醫
何景文醫生
龍浩鋒教授
吳福康醫生
杜健華教授
杜光旭博士
黃益昌先生
嚴子閣先生 (秘書)

(ii) Functions

The Pharmacy and Poisons (Registration of Pharmaceutical Products and Substances: Certification of Clinical Trial/ Medicinal Test) Committee is established to carry out the following functions in accordance with the Pharmacy and Poisons Regulations:

(a) consider new or renewal applications for registration of pharmaceutical products or substances, and issue registration certificates subject to any conditions it thinks fit to impose;

(b) deregister a pharmaceutical product or substance, suspend the registration of a pharmaceutical product or substance for a specified period, issue warning letter(s) to the holder of a registration certificate or vary a condition of the registration of pharmaceutical products or substances;

(c) consider applications for approval to change any of the registrable particulars of a pharmaceutical product or substance;

(d) consider applications for conducting a clinical trial on human beings or a medicinal test on animals, and issue a clinical trial certificate or medicinal test certificate, subject to any conditions it thinks fit to impose; and

(e) cancel a clinical trial certificate or medicinal test certificate, suspend a clinical trial certificate or medicinal test certificate for a specified period, issue warning letter(s) to the holder of the certificate or vary a condition of the certificate.

(ii) 職能

藥劑業及毒藥(藥劑製品及物質註冊：臨牀試驗及藥物測試證明書)委員會根據《藥劑業及毒藥規例》，執行下列職能：

(a) 在委員會認為適宜施加的條件的規限下，審議藥劑製品或物質的新註冊申請或續期註冊申請以及簽發註冊證明書；

(b) 撤銷藥劑製品或物質的註冊、在指明期間內暫時吊銷藥劑製品或物質的註冊、向有關註冊證明書持有人發出警告信或更改施加於藥劑製品或物質的註冊條件；

(c) 審議有關更改藥劑製品或物質註冊詳情的申請；

(d) 在委員會認為適宜施加的條件的規限下，審議有關對人類進行臨牀試驗或對動物進行藥物測試的申請以及簽發臨牀試驗證明書或藥物測試證明書；及

(e) 取消臨牀試驗證明書或藥物測試證明書、在指明期間內暫時吊銷臨牀試驗證明書或藥物測試證明書、向有關證明書的持有人發出警告信或更改施加於證明書的條件。

(6) Poisons Committee

(i) Membership as at 31 December 2020

Dr SIN Wai-mei, Della, JP (Chairman)
Dr SO Yui-chi
Mr CHAN Ling-fung, Frank
Mr SUNG Ming-tat, Dick
Professor WONG Chi-kei, Ian
Mr YAU Fuk-loi, Rico
Ms TANG Suk-man, Alice (Secretary)

(6) 毒藥委員會

(i) 截至二零二零年十二月三十一日的成員名單

單慧媚博士，JP (主席)
蘇睿智醫生
陳凌峯先生
沈明達先生
黃志基教授
邱福來先生
鄧淑雯女士 (秘書)

(ii) Functions

The Poisons Committee is set up under section 31 of the Pharmacy and Poisons Ordinance to advise the Board on the classification and distribution of poisons in Part 1 and Part 2 of the Poisons List and matters relating to the control of poisons and pharmaceutical products, including:

(a) the classification of pharmaceutical products pending registration; and

(b) the review of the classification of pharmaceutical products regulated under the Pharmacy and Poisons Regulations.

(ii) 職能

毒藥委員會根據《藥劑業及毒藥條例》第31條成立，就各種毒藥在毒藥表第1部及第2部中的分類及分配，以及有關管制毒藥及藥劑製品的事宜，向管理局提供意見。有關事宜包括：

(a) 有待註冊的藥劑製品的分類；及

(b) 檢討根據《藥劑業及毒藥規例》管制的藥劑製品的分類。

(7) Pharmacy Internship Training Committee

(i) Membership as at 31 December 2020

Professor ZUO Zhong, Joan (Chairman)
Mr CHAN Ling-fung, Frank
Mr CHENG Kit-man, MH
Mr CHEUNG Yiu-kwong, Alex
Ms HSUEH Cheung-mei, Vivian
Mr LAM Fung-shing, Edwin
Dr LAU Sze-ngar, Grace
Dr LEE Pui-man, Jeff
Dr LEUNG Pak-heng, George
Mr LOK Wing-huen, Winham
Professor TO Kin-wah, Kenneth
Dr TO Kwong-yuk
Mr WONG Ka-kin, Andy
Ms TANG Suk-man, Alice (Secretary)

(7) 藥劑師實習培訓委員會

(i) 截至二零二零年十二月三十一日的成員名單

左中教授 (主席)
陳凌峯先生
鄭結文先生，MH
張耀光先生
薛長薇女士
林豐盛先生
劉思雅博士
李培文醫生
梁栢行博士
駱永煊先生
杜健華教授
杜光旭博士
黃家健先生
鄧淑雯女士 (秘書)

(ii) Functions

The Pharmacy Internship Training Committee is set up under the Board to:

(a) assist the Board in the registration of internship training institutions and preceptors;

(b) assist the Board in drawing up the criteria for the approval of the content of the preceptor's quarterly appraisal forms and the intern's annual assessment forms proposed by the different training institutions and in implementing the criteria, and to establish sub-committees for these purposes where necessary;

(c) assist the Board in drawing up the criteria for the evaluation of the preceptor's quarterly appraisals and the intern's annual assessments and in implementing the criteria, and to establish sub-committees for these purposes where necessary;

(d) advise the Board on matters pertaining to pharmacy internship training;

(e) liaise with internship training institutions and with preceptors on matters pertaining to internship training as necessary; and

(f) carry out such other functions connected with internship training as may be permitted or assigned to the Committee by the Board.

(ii) 職能

藥劑師實習培訓委員會由管理局成立，負責：

(a) 協助管理局處理實習培訓機構及導師註冊事宜；

(b) 協助管理局制訂準則用以批核由不同培訓機構提交的導師所用的季度評核表格及實習人員所用的年度評核表格，以及執行這些準則並按需要設立小組委員會；

(c) 協助管理局制訂準則用以審核導師提交的季度評核表格及實習人員提交的年度評核表格，以及執行這些準則並按需要設立小組委員會；

(d) 就有關藥劑師實習培訓的事宜向管理局提供意見；

(e) 按需要與實習培訓機構及導師緊密聯絡；及

(f) 執行管理局所容許並賦予的有關實習培訓的其他職能。

The Work of the Board and its Committees
管理局及其委員會的工作

(1) Registration of Pharmacists

Any person intending to practise as a pharmacist in Hong Kong must first be registered with the Board. To be eligible for registration, an applicant must be able to meet the qualification, examination and training requirements specified by the Board.

(i) Qualification

An applicant must satisfy either one of the following two criteria:

(a) holds a pharmacy degree awarded by a recognized university in Hong Kong; or

(b) a non-locally trained applicant must have completed his/her tertiary education of not less than three full-time academic years, or equivalent, in pharmacy, and be registered or be professionally qualified to be registered as a pharmacist, normally in the country in which he/she has completed his/her studies in pharmacy.

(ii) Examination

An applicant who possesses the qualification in (i)(b) above must also pass the Board's registration examinations in three subjects, namely Pharmacy Legislation in Hong Kong, Pharmacy Practice and Pharmacology.

The Examination Committee conducted two registration examinations in June and December 2020. A total of 51 applicants cumulatively passed all the three subjects in the year 2020.

The results of these two registration examinations are shown in **Table 1**. Figures for 2016 to 2020 are also included for comparison purpose.

(iii) Training

Applicants holding a pharmacy degree awarded by a recognized university in Hong Kong are required to undergo Board-approved training for one year before they can be registered as pharmacists.

Applicants holding a recognized pharmacy degree awarded elsewhere should have had an aggregate of relevant pre-registration training and/or post-registration experience of not less than one year. An applicant with less than one year's training and experience may be permitted to take the registration examinations but, upon passing all parts thereof, will be required to undergo an appropriate period of make-up training specified by the Board.

(1) 藥劑師的註冊

擬於香港執業的藥劑師必須向管理局註冊。申請人必須具備管理局規定的資格、考試成績及實習履歷，方符合資格註冊。

(i) 資格

申請人必須符合下述其中一項條件：

(a) 具備香港認可大學頒授的藥劑學學位；或

(b) 在本港以外地區完成不少於三個完整學年或相等的藥劑學課程，並已在其完成學業的地區註冊為藥劑師；或取得註冊為藥劑師的專業資格。

(ii) 考試

符合上述(i)(b)項要求的申請人，必須通過由管理局舉辦的三個科目的註冊考試，包括香港藥劑法例、藥劑執業及藥理學。

考試委員會在二零二零年分別在六月及十二月舉辦了兩次註冊考試。同年共有51人累積取得全部三科合格的成績。

表 1 列出該兩次註冊考試的成績，以及二零一六年至二零二零年的有關數字，以供比較。

(iii) 實習

持有香港認可大學頒授的藥劑學學位的申請人，在獲准成為註冊藥劑師前，須接受管理局認可的實習訓練，為期一年。

持有其他地方頒發的認可藥劑學學位的申請人，他的註冊前實習訓練及／或取得註冊後的工作經驗，合共不可少於一年。訓練及經驗合共少於一年的申請人亦可獲得批准參加註冊考試，惟通過全部考試後，須接受一段管理局認可的補償實習。

(iv) Registration

Upon registration, the Secretary of the Board will issue to a registered pharmacist a certificate of registration.

The Secretary is also responsible for keeping a register of pharmacists in which particulars of all pharmacists registered in Hong Kong are entered. The register is open for inspection by the general public. A copy of the register is also published in the Gazette once every 12 months.

As at 31 December 2020, there were 3 097 registered pharmacists in Hong Kong. Statistical data regarding registration of pharmacists and breakdown of fresh registration, removal from the register and re-registration of pharmacists for 2016 to 2020 are shown in **Tables 2** and **3**.

(v) Practising Certificates

All practising pharmacists must obtain a practising certificate annually in accordance with section 10A of the Pharmacy and Poisons Ordinance.

(vi) Discipline of Pharmacists

Inquiries into the conduct of registered pharmacists are made by Disciplinary Committees appointed under section 15 of the Pharmacy and Poisons Ordinance. A registered pharmacist found guilty of misconduct will be subject to disciplinary sanctions, ranging from censure, written warning, to removal from the register of pharmacists for a specified period of time. A more detailed account of the set-up and work of Disciplinary Committees is given in pages 24 to 26 of this report.

Statistical data regarding disciplinary actions taken by the Board in respect of registered pharmacists in 2016 to 2020 are shown in **Tables 4**, **5** and **6**.

(iv) 註冊

一經註冊，管理局秘書會向註冊藥劑師發出註冊證明書。

管理局秘書負責備存一份藥劑師名冊，詳列所有在香港註冊的藥劑師的個人資料，並公開予市民查閱。該名冊每十二個月在憲報刊登一次。

截至二零二零年十二月三十一日，香港共有3 097位註冊藥劑師。**表2**及**3**列出二零一六年至二零二零年有關藥劑師註冊，以及新註冊、刪除註冊及重新註冊的分項數字的統計資料。

(v) 執業證明書

所有執業藥劑師必須根據《藥劑業及毒藥條例》第10A條的規定取得週年執業證明書。

(vi) 藥劑師的紀律事宜

管理局根據《藥劑業及毒藥條例》第15條的規定，委出紀律委員會，調查註冊藥劑師的行為操守。被裁定行為不當的註冊藥劑師將接受紀律制裁，包括被譴責、警告信或在指定的時期內從藥劑師名冊上除名。有關紀律委員會的組成及工作詳情，可參閱本年報第24至26頁。

表4、**5**及**6**詳列管理局在二零一六年至二零二零年對註冊藥劑師採取紀律行動的統計數字。

(2) Licensing and Regulatory Control of Retail Traders (Including Authorized Sellers of Poisons and Listed Sellers of Poisons)

(i) Authorized Sellers of Poisons: Licensing

An authorized seller of poisons ("ASP"), commonly known as "pharmacy" or "dispensary", is a business authorized to sell poisons included in Part 1 of the Poisons List, by or under the supervision of a registered pharmacist. Any person wishing to operate as an ASP shall apply to the Board for registration of the premises where the retail sale of poisons is to be conducted. Besides, ASPs are also authorized to conduct retail sale of poisons included in Part 2 of the Poisons List at registered premises. If the Board is satisfied that the requirements stipulated in section 13(4) of the Pharmacy and Poisons Ordinance are complied with, the application will be granted subject to payment of the prescribed fee.

The name, the certificate of registration and a notice setting out the attending hours of the duty pharmacist are required to be displayed in a conspicuous location in the premises of an ASP. The ASP may also display a logo prescribed under section 13A of the Pharmacy and Poisons Ordinance.

ASPs must apply for renewal of registration annually. All records of an ASP will be taken into account when the Board assesses its application for renewal of registration of premises each year. If the ASP is not considered a fit and proper person to continue the retail business of poisons, the application will be rejected.

There were 610 ASPs registered in Hong Kong as at the end of 2020. Statistical data regarding the total number of ASPs, applications for registration and renewal of registration of premises of ASPs in 2016 to 2020 are shown in **Tables 7** and **8**.

(2) 零售商(包括獲授權毒藥銷售商及列載毒藥銷售商)的發牌及規管工作

(i) 獲授權毒藥銷售商：發牌工作

獲授權毒藥銷售商一般稱為「藥房」("pharmacy"或"dispensary"),是獲授權銷售毒藥表內第1部毒藥的商號，惟銷售這些毒藥必須由註冊藥劑師監督或直接銷售。擬申請成為獲授權毒藥銷售商的商號，須向管理局申請將其進行毒藥零售業務的處所註冊。此外，獲授權毒藥銷售商亦會獲授權在註冊處所內零售毒藥表內第2部毒藥。如管理局信納該申請符合《藥劑業及毒藥條例》第13(4)條所列的條件，便批准有關申請，在繳付訂明費用後生效。

獲授權毒藥銷售商須在其處所的當眼處展示其當值藥劑師的姓名、註冊證明書及工作時間的告示。銷售商亦可以展示根據《藥劑業及毒藥條例》第13(A)條訂明的標識。

獲授權毒藥銷售商須每年向管理局申請註冊續期。管理局在審理獲授權毒藥銷售商的週年處所註冊續期申請時，會考慮有關銷售商的全部記錄。假如管理局認為該獲授權毒藥銷售商並不適宜繼續經營毒藥零售業務，管理局將拒絕其申請。

截至二零二零年年終，香港共有610名獲授權毒藥銷售商。**表7**及**8**詳列二零一六年至二零二零年獲授權毒藥銷售商的總數、處所註冊申請及註冊續期申請的統計數字。

(ii) Authorized Sellers of Poisons: Discipline

The premises registered with the Board are subject to inspection by pharmacist inspectors of the Department of Health. Test purchases to check illegal activities involving controlled drugs or unregistered pharmaceutical products are conducted and prosecutions are instituted against offenders.

Any act of alleged misconduct will be subject to inquiry by Disciplinary Committees appointed by the Board. If found guilty of misconduct, the ASP will be subject to disciplinary sanctions, ranging from written warning, variation on the conditions relating to the registration of premises to disqualification from being an ASP for a specified period of time.

Four inquiries were held in 2020 and all of the ASPs concerned were found guilty of misconduct. One ASP was issued with written warning whilst three others were disqualified from being an ASP for a period of time.

For minor infringement, if the pharmacist of the ASP concerned is directly involved in the case, the Board may direct the proprietor / director and duty pharmacist of the ASP to be interviewed by the Assistant Director (Drug) of the Department of Health and the Secretary of the Board and be given verbal cautions. Verbal caution may be given to the director / proprietor in the presence of the pharmacist when the pharmacist is not involved in the case. A total of 12 such interviews were held in 2020.

The number of inspections and test purchases conducted by pharmacist inspectors against ASPs in 2016 to 2020 is shown in **Table 9**.

Statistical data regarding disciplinary cases handled by the Board in respect of ASPs in 2016 to 2020 are given in **Tables 10**, **11**, **12** and **12A.**

(ii) 獲授權毒藥銷售商：紀律事宜

衞生署的藥劑師督察會巡查已經向管理局註冊的銷售商處所。署方亦會派員抽樣進行試買，偵查涉及受管制藥物或未經註冊藥劑製品的違法活動，並檢控違法者。

管理局會委出紀律委員會就任何不當行為展開研訊。銷售商如被裁定犯有不當行為，將會受到紀律制裁，由書面警告、更改處所註冊條件，以至在指定期間被取消銷售商資格。

在二零二零年，管理局舉行了四次紀律研訊，全部涉事的獲授權毒藥銷售商被裁定犯有不當行為。紀律委員會向其中一名獲授權毒藥銷售商發出書面警告，三名獲授權毒藥銷售商則被取消銷售商資格一段時間。

至於輕微的違法行為，如獲授權毒藥銷售商的藥劑師直接牽涉其中，管理局會指示衞生署助理署長(藥物)及管理局秘書，約見有關的獲授權毒藥銷售商的東主或董事及當值藥劑師，向他們發出口頭警告；如獲授權毒藥銷售商的藥劑師沒有牽涉在內，則獲授權毒藥銷售商的東主或董事必須於其藥劑師在場的情況下出席晤談，接受口頭警誡。管理局在二零二零年舉行了12次該類會面。

表9列出二零一六年至二零二零年由藥劑師督察對獲授權毒藥銷售商進行巡查及試買的數字。

表10、**11**、**12**及**12A**詳列二零一六年至二零二零年管理局處理有關獲授權毒藥銷售商的紀律個案的統計數字。

(iii) Listed Sellers of Poisons: Licensing

A listed seller of poisons ("LSP"), commonly known as a medicine company, is a person approved to conduct the retail sale of poisons included in Part 2 of the Poisons List subject to the provision of the Pharmacy and Poisons Ordinance. Any person wishing to operate as a LSP should apply for his name to be entered onto the list of LSPs kept by the Board. On behalf of the Board, the Pharmacy and Poisons (Listed Sellers of Poisons) Committee issues licences to LSPs.

There were 4 187 LSPs in Hong Kong as at the end of 2020. The number of licensed LSPs in 2016 to 2020 is shown in **Table 13**. Statistical data regarding applications for LSP licences in these five years are shown in **Table 14**.

(iv) Listed Sellers of Poisons: Discipline

Like ASPs, LSPs are also subject to inspection by pharmacist inspectors but unlike ASPs, no disciplinary inquiries by Disciplinary Committees are held to inquire into the conduct of a LSP. If a LSP is convicted of any offence under the Pharmacy and Poisons Ordinance, the Antibiotics Ordinance, the Dangerous Drugs Ordinance, the Trade Descriptions Ordinance, or the LSP has contravened the Code of Practice or licensing conditions, his case will be submitted to the Board for consideration. If the Board considers him not a fit and proper person to continue the retail business of Part 2 poisons, his name will be removed or suspended for a period specified by the Board from the list of LSPs. For minor infringement, the Board may issue a written warning to the LSP concerned.

The number of inspections and test purchases conducted by pharmacist inspectors on LSPs in 2016 to 2020 is shown in **Table 15**. Statistical data regarding disciplinary cases handled by the Board in respect of LSPs in these five years are given in **Tables 16**, **17** and **17A**.

(iii) 列載毒藥銷售商：發牌工作

列載毒藥銷售商一般稱為藥行，是根據《藥劑業及毒藥條例》的規定，獲准經營毒藥表內第2部毒藥零售業務的人士。擬成為列載毒藥銷售商的人士，可向管理局申請將其姓名載入管理局備存的列載毒藥銷售商名單內。藥劑業及毒藥(列載毒藥銷售商)委員會會代表管理局簽發牌照予列載毒藥銷售商。

截至二零二零年年終，香港共有4187名列載毒藥銷售商。**表13**列出二零一六年至二零二零年列載毒藥銷售商的總數。**表14**列出在上述五年申請發牌的統計數字。

(iv) 列載毒藥銷售商：紀律事宜

衞生署藥劑師督察同樣地會巡查列載毒藥銷售商的處所。但是，管理局不會因調查列載毒藥銷售商的經營手法而召開紀律研訊，這點與處理有關獲授權毒藥銷售商的紀律事宜的方法不同。假如有列載毒藥銷售商被裁定干犯任何《藥劑業及毒藥條例》、《抗生素條例》、《危險藥物條例》、《商品説明條例》或違反其《執業守則》或發牌條件，有關個案將直接呈交管理局考慮。管理局假如認為涉案的列載毒藥銷售商並不適宜繼續經營第2部毒藥零售業務，便會把該列載毒藥銷售商的姓名從列載毒藥銷售商名單上刪除或在指明的期間內暫時吊銷其名列該名單內的資格。至於輕微的違法行為，管理局可向有關的列載毒藥銷售商發出書面警告。

表15列出二零一六年至二零二零年由藥劑師督察對列載毒藥銷售商進行巡查以及試買的數字。**表16**、**17**及**17A**詳列管理局在上述五年處理有關列載毒藥銷售商的紀律個案的統計數字。

(3) Licensing and Regulatory Control of Wholesalers and Manufacturers

(i) Wholesale Dealers of Pharmaceutical Products

Subject to the provisions of the Pharmacy and Poisons Regulations, any person wishing to deal in wholesale and/or import / export of poisons and/or pharmaceutical products should apply to the Pharmacy and Poisons (Wholesale Licences) Committee for an annual wholesale dealer licence.

A licensed wholesale dealer must keep a record of all transactions involving poisons included in Part 1 of the Poisons List or any pharmaceutical product. Sales of poisons are restricted to authorized persons only.

There were 786 holders of wholesale dealer licence in Hong Kong as at the end of 2020. Statistical data for 2016 to 2020 are shown in **Table 18**.

(ii) Manufacturers of Pharmaceutical Products

Any person wishing to manufacture any pharmaceutical product should apply to the Pharmacy and Poisons (Manufacturers Licensing) Committee for a licence annually.

Manufacturers are subject to the provisions of the Pharmacy and Poisons Regulations. They are required to label the container of each pharmaceutical product with the appropriate particulars, such as the active constituents or ingredients of the product, the quantitative particulars of these constituents or ingredients, and the name and address of the manufacturer. They are also required to take adequate steps to ensure that all personnel involved in the manufacturing or packing of pharmaceutical products do not contaminate or infect the products.

It is the duty of every manufacturer to test each batch of raw material intended to be used in the manufacture of pharmaceutical products to ensure identity and purity, and to test its finished form to ensure identity and potency. A system of control that will enable the rapid and complete recall of any product from sale to the public should be put in place.

A manufacturer should also ensure that the premises and the fittings and machinery in such premises meet an appropriate standard in respect of temperature, humidity, cleanliness and hygiene, and that a set of records regarding the manufacture of pharmaceutical products is properly kept.

(3) 批發商及製造商的發牌及規管工作

(i) 藥劑製品批發商

除《藥劑業及毒藥規例》另有規定外，任何人如欲經營毒藥及/或藥劑製品批發及/或進/出口，均須向藥劑業及毒藥(批發牌照)委員會申請一年期的批發商牌照。

持牌的批發商須備存所有涉及毒藥表第1部所列毒藥或所有藥劑製品的交易記錄，而銷售對象只限於獲授權人士。

截至二零二零年年終，香港共有786名批發商牌照持有人。**表18**列出二零一六年至二零二零年的統計數字。

(ii) 藥劑製品製造商

任何人如欲製造任何藥劑製品，每年均須向藥劑業及毒藥(製造商牌照)委員會申請牌照。

製造商必須遵守《藥劑業及毒藥規例》的規定，他們須在每件藥劑製品的容器上加上適當的標籤，標明製品的成分或有效組分、該等成分或組分的數量詳情、製造商的名稱及地址等資料。他們並須採取足夠的步驟，確保所有從事製造或包裝藥劑製品的人員不會污染該等製品或使該等製品受到感染。

每名製造商必須測試擬用於製造藥劑製品的每一批原料，確保原料的本質及純度；及測試製成品，以確保其本質及效力。製造商亦須設立一套管理制度，以便能向市場迅速地完全回收任何正在銷售的產品。

製造商同時須確保其廠房以及其裝置及機器符合溫度、濕度、清潔及衞生的標準，以及備存一套有關生產藥劑製品的記錄。

The manufacture of pharmaceutical products must be supervised by a registered pharmacist or persons with such other qualifications as approved by the Board. A manufacturer must also ensure that at least one authorized person is employed to be responsible for ensuring and certifying that the pharmaceutical products are manufactured in accordance with the Pharmaceutical Inspection Co-operation Scheme Good Manufacturing Practice ("PIC/S GMP") Guide and registration requirements.

There were 69 holders of a manufacturer's licence in Hong Kong as at the end of 2020, and all of them were required to comply with the GMP Guide with effect from 1 October 2015. Among these 69 holders, 46 holders were only authorized to conduct secondary packaging of pharmaceutical products. Statistical data of manufacturer's licences and the authorized persons for 2016 to 2020 are given in **Tables 19 and 20** respectively.

製造藥劑製品必須在註冊藥劑師或具備管理局認可資格的人士監督下進行。製造商須僱用最少一名獲授權人士負責確保及保証所製造的藥劑製品符合國際醫藥品稽查協約組織的生產質量管理規範指引及註冊資格。

截至二零二零年年終，香港共有69名製造商牌照持有人。由2015年10月1日起，所有牌照持有人均須符合國際醫藥品稽查協約組織的生產質量管理規範指引。而69名製造商牌照持有人當中，46名只獲授權從事藥劑製品外包裝操作。**表19**及**20**分別列出二零一六年至二零二零年製造商牌照及獲授權人士的統計數字。

(4) Registration and Classification of Pharmaceutical Products

(i) Registration of Pharmaceutical Products

In accordance with regulation 36 of the Pharmacy and Poisons Regulations, any person wishing to sell, offer for sale, distribute or possess any pharmaceutical product or substance, shall register the product or substance with the Pharmacy and Poisons (Registration of Pharmaceutical Products and Substances: Certification of Clinical Trial/ Medicinal Test) Committee.

In considering an application for registration of a pharmaceutical product, the Committee will take into account the safety, efficacy and quality of the subject product. In dealing with an application manufactured outside Hong Kong, the Committee may require the applicant to take any or all of the following actions:

(a) produce an undertaking to permit the Committee to inspect the manufacturing premises;

(b) produce a declaration that the subject product is manufactured in accordance with the requirements imposed by or under the law of the country concerned; and

(c) pay a fee as representing the expenditure incurred by or on behalf of the Committee in carrying out an inspection at the manufacturing premises.

(4) 藥劑製品的註冊及分類

(i) 藥劑製品的註冊

根據《藥劑業及毒藥規例》第36條的規定，任何人如欲銷售、要約出售、分銷或管有任何藥劑製品或物質，均須將有關製品或物質向藥劑業及毒藥(藥劑製品及物質註冊：臨牀試驗及藥物測試證明書)委員會註冊。

在決定是否批准某一藥劑製品註冊時，委員會會考慮該藥品的安全程度、效能及素質。處理在香港境外製造的產品的申請時，委員會可能要求申請人出示下列其中一份或全部文件：

(a) 准許委員會視察其生產廠房的承諾書；

(b) 承諾該產品是遵照有關國家的法律或根據法律施加的任何規定而製造的聲明書；及

(c) 繳付由委員會釐定的費用，該筆費用相當於委員會或其代表在視察生產廠房時所招致或相當可能招致的開支。

A registration certificate will be issued on registration of a pharmaceutical product, and will be subject to any conditions the Committee thinks fit to impose. The applicant will also be advised of the classification of the product.

There were 15 396 registered pharmaceutical products in Hong Kong as at the end of 2020. The number of registered pharmaceutical products as at the end of 2016 to 2020 is shown in **Table 21**.

(ii) Classification of Pharmaceutical Products

On the advice of the Poisons Committee, the Board determines and reviews the classification and distribution of pharmaceutical products in the Poisons List and regulates their control by posing further restrictions on their sales through the provision of Schedules 1 and 3 of the Pharmacy and Poisons Regulations. The classification of pharmaceutical products in Schedule 10, i.e. Poisons List, and restrictions on sales under the two schedules are:

Classification	Restriction(s) on sale
(a) Part 1 Poisons: Poisons included in Part 1 of Schedule 10, i.e. Poisons List	They can be sold only by authorized sellers of poisons under the supervision of registered pharmacists. They should also be stored in retail premises in a locked receptacle in a part of the premises to which customers do not have access.
(b) Schedule 1 Poisons: Poisons included in Part 1 of Schedule 10, i.e. Poisons List, and Schedule 1 to the Pharmacy and Poisons Regulations	They can be sold only by authorized sellers of poisons under the supervision of registered pharmacists and after entry in the poisons book stating the particulars of the sale.
(c) Schedule 3 Poisons: Poisons included in Part 1 of Schedule 10, i.e. Poisons List, and Schedule 3 to the Pharmacy and Poisons Regulations	They can be sold only by authorized sellers of poisons under the supervision of registered pharmacists with the authority of a prescription from a registered medical practitioner, registered dentist or registered veterinary surgeon.
(d) Part 2 Poisons: Poisons included in Part 2 of Schedule 10, i.e. Poisons List	They can be sold by listed sellers of poisons and authorized sellers of poisons without the supervision of registered pharmacists.

一經註冊，受委員會認為適宜施加的條件的規限下，申請者會獲發註冊證明書，並獲告知產品的分類。

截至二零二零年年終，香港共有15 396種已註冊的藥劑製品。**表21**列出截至二零一六年至二零二零年年終的註冊藥劑製品數字。

(ii) 藥劑製品的分類

就毒藥委員會的建議，管理局會決定及檢討藥劑製品在毒藥表內的分類及分配，並透過《藥劑業及毒藥規例》附表1和附表3，進一步規管藥劑製品的銷售。藥劑製品在附表10，即毒藥表，的各種不同分類及在附表1和附表3內的銷售規管分述如下：

分類	銷售的限制
(a)第1部毒藥：附表10，即毒藥表，第1部所列毒藥	在註冊藥劑師監督下，由獲授權毒藥銷售商銷售。這類毒藥必須存放在上鎖的盛器內，而盛器則須存放在處所內顧客不准進入的地方。
(b) 附表1毒藥：同時列於附表10，即毒藥表，第1部及《藥劑業及毒藥規例》附表1的毒藥	在註冊藥劑師監督下，由獲授權毒藥銷售商銷售，並必須於出售前將銷售詳情記錄在毒藥冊中。
(c)附表3毒藥：同時列於附表10，即毒藥表，第1部及《藥劑業及毒藥規例》附表3的毒藥	須由註冊醫生、註冊牙醫或註冊獸醫處方授權，並在註冊藥劑師監督下，由獲授權毒藥銷售商銷售。
(d)第2部毒藥：附表10，即毒藥表，第2部所列毒藥	無須藥劑師監督，由列載毒藥銷售商或獲授權毒藥銷售商銷售。

Regulatory provisions in other related areas are contained in Schedules 2 and 4 to 7 to the Pharmacy and Poisons Regulations:

Schedule	Provisions
Schedule 2	providing for certain articles to be exempted from some of the provisions of the Pharmacy and Poisons Ordinance and the Pharmacy and Poisons Regulations
Schedule 4	setting out the statement of particulars as to proportion of poisons in certain cases
Schedule 5	prescribing the labelling requirements for certain poisons
Schedule 6	listing out certain poisons which are exempted from labelling provisions when sold or supplied in certain circumstances
Schedule 7	listing out certain poisons which are required to be specially labelled for transport

Classification and distribution in Schedule 10, i.e. Poisons List, and imposition of control through the various schedules were made through amendments to the Pharmacy and Poisons Regulations. Amendments proposed by the Board and approved by the Legislative Council in 2020 are shown in **Tables 22 and 23.**

《藥劑業及毒藥規例》附表2、附表4至7詳列對下述其他方面的規管：

附表	內容
附表2	列舉豁免受《藥劑業及毒藥條例》及《藥劑業及毒藥規例》一些條文規限的某些物品
附表4	詳列在某些情況下有關毒藥比例的詳情說明
附表5	說明對某些毒藥的標籤要求
附表6	列出在某些情況下銷售或供應則無須加上標籤的某些毒藥
附表7	列出為運輸而須特別加上標籤的某些毒藥

管理局透過修訂《藥劑業及毒藥規例》，將藥劑製品在附表10，即毒藥表內分類和分配，並透過多個附表對藥劑製品施加規管。立法會在二零二零年批准管理局就藥劑製品分類對《藥劑業及毒藥規例》作出的修訂列載於**表22**及**23**。

Membership and Functions of the Disciplinary Committee
紀律委員會的成員及職能

(1) Membership

A Disciplinary Committee consists of the following persons:

(a) a Chairman, who is the medical officer in the Department of Health appointed by the Chief Executive under section 3(2)(e) of the Pharmacy and Poisons Ordinance as a member of the Board;

(b) two registered pharmacists (not being public officers) nominated by the Pharmaceutical Society of Hong Kong; and

(c) a legal adviser appointed by the Chief Executive.

As at 31 December 2020, the Chairman of the Disciplinary Committee was Dr CHIU Pui-yin, Amy, JP, Controller, Regulatory Affairs of the Department of Health. Registered pharmacists who had served as members in 2020 included:

Ms CHEUNG Oi-ling
Ms KUNG Wai-yiu
Mr LEUNG Kwong-hei, Kenneth
Ms MOK Lai-fong
Mr NG Wing-yan
Ms TAM Hi
Mr WONG Chi-ming
Mr WONG Kwong-cheung, Aaron

(1) 成員

紀律委員會的成員包括下列人士：

(a) 一名根據《藥劑業及毒藥條例》第3(2)(e)條由行政長官委任為管理局成員的衞生署醫生，並由其出任主席；

(b) 兩名由香港藥學會提名的註冊藥劑師(非公職人員)；及

(c) 一名由行政長官委任的法律顧問。

衞生署規管事務總監趙佩燕醫生，JP是紀律委員會在二零二零年十二月三十一日的主席。曾在二零二零年出任成員的註冊藥劑師包括：

張靄玲女士
龔瑋珧女士
梁廣熙先生
莫麗芳女士
吳榮恩先生
譚起女士
黃志明先生
黃廣長先生

(2) Functions

In accordance with section 15 of the Pharmacy and Poisons Ordinance, a Disciplinary Committee is appointed by the Board for the purpose of disciplinary inquiry if:

(a) a complaint is received by the Board regarding the conduct of a registered pharmacist or an employee of a registered pharmacist, or it appears to the Board that a registered pharmacist has contravened a code of conduct applicable to the registered pharmacist;

(b) a complaint is received by the Board regarding the conduct of an authorized seller of poisons ("ASP") or an employee, officer or partner of an ASP, or it appears to the Board that an ASP has contravened a code of practice applicable to the ASP;

(c) any of the persons mentioned in (a) or (b) above, is convicted of an offence under:

  i) the Pharmacy and Poisons Ordinance, the Dangerous Drugs Ordinance, the Antibiotics Ordinance, the Undesirable Medical Advertisements Ordinance; or

  ii) section 52, 54 or 61 of the Public Health and Municipal Services Ordinance or section 7, 7A or 9 of the Trade Descriptions Ordinance;

(d) it appears to the Board that a condition imposed under section 13 of the Pharmacy and Poisons Ordinance in respect of the registration of any premises of an ASP has been contravened; or

(e) it otherwise appears necessary or desirable to the Board to inquire into the conduct of any of the persons mentioned in (a) or (b) above.

In respect of a registered pharmacist or an employee of a registered pharmacist, the Disciplinary Committee may, at the conclusion of an inquiry:

(a) censure the registered pharmacist;

(b) issue a warning letter to the registered pharmacist; or

(c) remove his name from the register of pharmacists and not to re-enter it thereon for such period as the Disciplinary Committee directs.

As for an ASP or an employee, officer or partner of an ASP, the Disciplinary Committee may at the conclusion of an inquiry direct that:

(a) the ASP be disqualified, for such period as may be specified in the direction, from being an ASP;

(2) 職能

根據《藥劑業及毒藥條例》第15條，管理局委出紀律委員會就下列情況召開紀律研訊：

(a) 當管理局接到有關某註冊藥劑師或其僱員的行為操守的投訴，或管理局覺得某藥劑師已違反適用於該藥劑師的《行為守則》；

(b) 當管理局接到有關某獲授權毒藥銷售商、其僱員、高級人員或合夥人的行為操守的投訴；或管理局覺得某獲授權毒藥銷售商已違反適用於該銷售商的《執業守則》；

(c) 當上述(a)或(b)項所述的任何人士被裁定干犯：

  (i) 《藥劑業及毒藥條例》、《危險藥物條例》、《抗生素條例》或《不良廣告(醫藥)條例》所訂罪行；或

  (ii) 《公眾衞生及市政條例》第52、54或61條或《商品説明條例》第7、7A或9條所訂罪行；

(d) 當管理局覺得根據《藥劑業及毒藥條例》第13條就某獲授權毒藥銷售商的處所的註冊而施加的某條件，遭人違反；或

(e) 當管理局在其他情況下，覺得有需要或適宜就任何在(a)或(b)段所述的人的行為操守進行研訊。

如研訊是就某註冊藥劑師或其僱員而進行，紀律委員會可在研訊完結時：

(a) 譴責該藥劑師；

(b) 向該藥劑師發出警告信；或

(c) 在紀律委員會指示的期間內，將該藥劑師的姓名從藥劑師名冊中刪除。

至於獲授權毒藥銷售商或其僱員、高級人員或合夥人，紀律委員會可在研訊完結時作出下列指示：

(a) 在某一指定的期間內，取消該銷售商的獲授權毒藥銷售商的資格；

(b) any or all of the premises of that ASP be removed from the register of premises, either until the expiry of the certificate of registration issued to that ASP in respect of the premises, or for a shorter period as may be specified in the direction;

(c) variations be made to the conditions relating to the registration of any or all of the premises of that ASP; or

(d) a warning letter be served on that ASP.

At the conclusion of a disciplinary inquiry, the direction of the Disciplinary Committee against a registered pharmacist or an ASP takes effect immediately if the Disciplinary Committee considers it in the public interest to bring the direction into immediate effect. In other cases, the direction takes effect on the date specified by the Disciplinary Committee if no appeal has been lodged before the expiry of the period for lodging an appeal. If an appeal has been lodged, the direction takes effect on the date on which the appeal is finally determined.

The Disciplinary Committee may, subject to any conditions it thinks fit to impose, suspend for a period not exceeding three years (suspension period) the operation of a direction to remove a pharmacist's name from the register of pharmacists, disqualify a person from being an ASP, or remove any or all of the premises of an ASP from the register of premises so that the direction takes effect only if a condition so imposed is contravened during the suspension period.

The Disciplinary Committee may, subject to any appeal, cause its decision in any inquiry to be published in the Gazette, with or without an account of the proceedings. An appeal against any direction of the Disciplinary Committee shall be made, within 28 days after receipt of notice of direction, to the Court of First Instance.

Statistical figures on the results of disciplinary inquiries into the conduct of registered pharmacists and ASPs are given in **Tables 5** and **11** respectively. There was no appeal to the Court of First Instance in 2020.

(b) 從處所註冊記錄冊中刪除該銷售商的任何或全部處所，直至向該銷售商發出的有關處所註冊證明書的有效期屆滿，或為期一段在該項指示指明較短的時間；

(c) 更改該銷售商的任何或全部處所的註冊條件；或

(d) 向該獲授權毒藥銷售商送達警告信。

紀律委員會在研訊完結時，如認為其就某註冊藥劑師或某獲授權毒藥銷售商作出的指示即時生效是合乎公眾利益，可指示即時生效；或在其他情況下如沒有上訴在限期屆滿前提出，則於紀律委員會指明的日期生效或如有上訴提出，則於該上訴獲最終裁定的日期生效。

紀律委員會可在適宜施加的條件的規限下，暫緩執行其作出將某藥劑師的姓名從藥劑師名冊中除去、取消某銷售商的獲授權毒藥銷售商的資格，或將某獲授權毒藥銷售商的任何或全部處所從處所註冊紀錄冊中除去的指示，為期不超過三年(暫緩期)，令到只有如此施加的條件在暫緩期內遭違反，該指示才會生效。

如有關人士不提出上訴，紀律委員會便可安排將其指令在憲報刊登，並可刊登或不刊登有關研訊程序的報告。有關人士欲就紀律委員會作出的指令提出上訴，須於收到指示通知書的二十八日內，向原訟法庭提出。

表5及**11**分別詳載有關註冊藥劑師及獲授權毒藥銷售商的紀律研訊結果的統計數字。二零二零年，原訟法庭沒有收到任何上訴申請。

Membership and Functions of the Pharmacy and Poisons Appeal Tribunal
藥劑業及毒藥上訴審裁處的成員及職能

(1) Membership

The Tribunal consists of the following members who are appointed by the Chief Executive in accordance with section 30(2) of the Pharmacy and Poisons Ordinance:

(a) a legally qualified person who shall be the chairman of the Tribunal;
(b) a registered medical practitioner;
(c) a registered pharmacist;
(d) a person qualified in pharmacology;
(e) a person nominated by the Director of Health from a panel consisting of persons nominated by pharmacists' associations;
(f) a person nominated by the Director of Health from a panel consisting of persons nominated by pharmaceutical industry associations; and
(g) a person nominated by the Director of Health from a panel consisting of persons nominated by the retail pharmaceutical trade associations.

The membership of the Tribunal as at 31 December 2020 was as follows:

Name	Membership
Mr WONG Kai-ming, Stewart, S.C.	Chairman
Dr TSANG Ho-fai, Thomas	Member
Dr LAM Ka-wing, Jenny	Member
Professor CHOW Yee-kwan, Elaine	Member
Miss CHU Man-wa	Panel Member
Mr SUEN Yiu-chan, Peter	Panel Member
Miss TANG Choi-hung	Panel Member
Mr CHAN Cho-sun	Panel Member
Mr WONG Kwok-kai	Panel Member
Mr WOO Pui-hong, Christopher	Panel Member
Mr CHENG Kin-tung, Johnny	Panel Member
Mr PANG Hok-ming	Panel Member
Mr YEUNG Chi-fat	Panel Member

(1) 成員

審裁處包括下列根據《藥劑業及毒藥條例》第30(2)條由行政長官委任的人士：

(a) 一名具備法律專業資格的人士，並由其出任審裁處主席；
(b) 一名註冊醫生；
(c) 一名註冊藥劑師；
(d) 一名具備藥理學資格的人士；
(e) 一名由藥劑師組織提名組成的小組的成員，並為衞生署署長提名的人士；
(f) 一名由藥劑業組織提名組成的小組的成員，並為衞生署署長提名的人士；及
(g) 一名由藥劑零售業組織提名組成的小組的成員，並為衞生署署長提名的人士。

在二零二零年十二月三十一日，審裁處的成員如下：

姓名	成員
黃繼明先生，SC	主席
曾浩輝醫生	委員
林嘉穎博士	委員
周怡君教授	委員
朱敏華女士	小組委員
孫耀燦先生	小組委員
鄧彩紅女士	小組委員
陳祖新先生	小組委員
黃國佳先生	小組委員
胡培康先生	小組委員
鄭健東先生	小組委員
彭鶴鳴先生	小組委員
楊志發先生	小組委員

(2) Functions

The Pharmacy and Poisons Appeal Tribunal, established under section 30 of the Pharmacy and Poisons Ordinance, hears and determines the following matters:

(a) any appeal against a decision of the Board in respect of application for registration of premises or application for renewal of registration of premises of an authorized seller of poisons;

(b) any appeal against a direction of the Board in respect of suspension or removal of the name of a listed seller of poisons ("LSP") from the list of LSPs; and

(c) any appeal against a decision of a committee of the Board, excluding the Disciplinary Committee.

No appeal was received by the Tribunal from 2016 to 2020.

(2) 職能

藥劑業及毒藥上訴審裁處根據《藥劑業及毒藥條例》第30條成立，負責聆訊和裁定下列事宜：

(a) 就管理局對獲授權毒藥銷售商的處所註冊申請或處所註冊續期申請的決定而提出的上訴；

(b) 就管理局對從列載毒藥銷售商名單中暫時吊銷或刪除列載毒藥銷售商資格的決定而提出的上訴；及

(c) 就管理局屬下的委員會的決定提出的上訴，惟紀律委員會的決定除外。

由二零一六年至二零二零年審裁處沒有收到研訊上訴。

Statistical Tables and Charts
統計圖表

Table 表 1

Results of the Registration Examinations
註冊考試成績

Year 年份	Pharmacy Legislation in Hong Kong 香港藥劑法例			Pharmacy Practice 藥劑執業			Pharmacology 藥理學		
	No. sat 參加人數	No. passed 合格人數	passing % 合格率	No. sat 參加人數	No. passed 合格人數	passing % 合格率	No. sat 參加人數	No. passed 合格人數	passing % 合格率
2016	159	68	42.8	194	46	23.7	181	44	24.3
2017	147	71	48.3	206	67	32.5	219	55	25.1
2018	143	78	54.5	203	52	25.6	205	92	44.9
2019	135	77	57.0	250	82	32.8	192	71	37.0
2020	73	49	67.1	140	37	26.4	98	56	57.1

Number of Candidates Sitting Each Examination Subject
每科考試的考生人數







Passing Percentage in Each Examination Subject
每科考試的合格率







Table 表 2

Number of Registered Pharmacists in Hong Kong
香港註冊藥劑師人數

Year 年份	2016	2017	2018	2019	2020
Number of registered pharmacists as at the end of the year 截至年終的註冊藥劑師人數	2 659	2 753	2 890	3 001	3 097



Statistical Tables and Charts
統計圖表

Table 表 3

Breakdown of Fresh Registration, Removal from the Register and Re-registration of Pharmacists
新註冊、刪除註冊及重新註冊的分項數字

Year 年份	2016	2017	2018	2019	2020
Fresh registration (Non-local graduates) 新註冊(非本地畢業)	67	36	78	55	53
Fresh registration (Local graduates) 新註冊(本地畢業)	98	79	80	75	73
Removal from the register* 刪除註冊*	12	25	22	21	30
Re-registration 重新註冊	2	4	1	2	0
Net increase 淨增長	155	94	137	111	96

*excluding orders by the Disciplinary Committee
* 不包括紀律委員會的指令

Table 表 4

Disciplinary Actions against Registered Pharmacists Taken by the Pharmacy and Poisons Board
藥劑業及毒藥管理局對註冊藥劑師採取的紀律行動

Disciplinary actions taken 採取的紀律行動	Number of cases 個案數目				
	2016	2017	2018	2019	2020
Formal disciplinary actions (i.e. Inquiry by Disciplinary Committee) 正式紀律行動 (即由紀律委員會進行紀律研訊)	1	0	0	1	0

Statistical Tables and Charts
統計圖表

Table 表 5

Results of Disciplinary Inquiries into Registered Pharmacists
對註冊藥劑師進行紀律研訊的結果

Findings of the Disciplinary Committee 紀律委員會的裁決	Number of cases 個案數目				
	2016	2017	2018	2019	2020
Charge dismissed 指控不成立	1	0	0	0	0
Guilty of the charge 指控成立	0	0	0	1	0
Directions of the Disciplinary Committee 紀律委員會的指示					
Censure 譴責	0	0	0	1	0
Removed from the register for a period of time 從名冊除名一段時間	0	0	0	0	0

Table 表 6

Disciplinary Cases regarding Registered Pharmacists Handled by the Pharmacy and Poisons Board
藥劑業及毒藥管理局處理有關註冊藥劑師的紀律個案

Nature of offences* 個案性質*	Number of counts 次數				
	2016	2017	2018	2019	2020
(1) Professional misconduct 專業失德	1	0	0	0	0
(2) Selling Schedule 3 poison(s) without the authority of a prescription 在沒有處方授權的情況下出售附表3毒藥	0	0	0	1	0
(3) Failing to keep proper record of antibiotics 沒有備存抗生素的適當記錄	0	0	0	1	0

* Some cases involve multiple nature of offences
* 部份個案涉及多個罪行

Table 表 7

Number of Authorized Sellers of Poisons in Hong Kong
香港的獲授權毒藥銷售商數目

Year 年份	2016	2017	2018	2019	2020
Number of authorized sellers of poisons as at the end of the year 截至年終的獲授權毒藥銷售商數目	604	614	641	649	610



Statistical Tables and Charts
統計圖表

Table 表 8

Applications for Registration of Premises of Authorized Sellers of Poisons
獲授權毒藥銷售商的處所註冊申請

Year 年份	2016	2017	2018	2019	2020
Number of applications for registration of premises approved 接納處所註冊申請的數目	29	37	50	51	23
Number of applications for registration of premises rejected 拒絕處所註冊申請的數目	0	0	0	0	0
Number of applications for renewal of registration of premises rejected 拒絕處所註冊的續期申請數目	0	1	0	0	0

Table 表 9

Regulatory Control of Authorized Sellers of Poisons
獲授權毒藥銷售商的規管

Year 年份	2016	2017	2018	2019	2020
Number of inspections conducted 巡查數目	1 209	1 220	1 212	1 305	1 060
Number of test purchases conducted 試買數目	3 955	4 329	4 194	4 101	2 664

Note: The numbers of inspections and test purchases in 2020 decreased due to the impact of the COVID-19 pandemic and the social distancing measures.

註： 2020 年的巡查和試買數目受 2019 冠狀病毒病疫情及社交距離措施影響而減少。

Table 表 10

Disciplinary Actions against Authorized Sellers of Poisons Taken by the Pharmacy and Poisons Board
藥劑業及毒藥管理局對獲授權毒藥銷售商採取的紀律行動

Disciplinary actions taken 採取的紀律行動	Number of cases 個案數目				
	2016	2017	2018	2019	2020
Formal disciplinary actions (i.e. Inquiry by Disciplinary Committee) 正式紀律行動（即由紀律委員會進行紀律研訊）	12	9	11	11	4
Informal disciplinary actions (i.e. Verbal caution by representatives of the Board) 非正式紀律行動（即由管理局代表給予口頭警告）	18	8	5	6	12
The authorized seller of poisons ceased operation before action taken by the Board 該銷售商在管理局採取紀律行動前已經結業	1	0	1	1	2
Total 總數	31	17	17	18	18

Statistical Tables and Charts
統計圖表

Table 表 11

Results of Disciplinary Inquiries into Authorized Sellers of Poisons
對獲授權毒藥銷售商進行紀律研訊的結果

Findings of the Disciplinary Committee 紀律委員會的裁決	Number of cases 個案數目				
	2016	2017	2018	2019	2020
Charge dismissed 指控不成立	0	0	0	0	0
Guilty of the charge 指控成立	12	9	11*	11	4
Directions of the Disciplinary Committee 紀律委員會的指示					
Issue of written warning 發出書面警告	4	0	3	6	1
Disqualified from being an authorized seller of poisons for a period of time 取消銷售商資格一段時間	8	9	7	5	3

*The decision of the Disciplinary Committee against one authorized seller of poisons was reversed by the Court of First Instance.
*原訟法庭推翻了紀律委員會對一名獲授權毒藥銷售商的裁決。

Table 表 12

Disciplinary Inquiries into Authorized Sellers of Poisons Handled by the Pharmacy and Poisons Board
藥劑業及毒藥管理局處理有關獲授權毒藥銷售商的紀律研訊個案

Nature of offences* 個案性質*	Number of counts (percentage) 次數 (百份比)				
	2016	2017	2018	2019	2020
(1) Sale of Part 1/Part 2 poison(s) without label/proper label 銷售沒有標籤/沒有妥善標籤的第1部或第2部毒藥	0 (0%)	0 (0%)	1 (4.17%)	0 (0%)	0 (0%)
(2) Sale of Part 1 poison(s) without the supervision of a registered pharmacist/ proper supervision 在沒有註冊藥劑師監督/適當監督的情況下銷售第1部毒藥	4 (12.9%)	6 (20.69%)	4 (16.66%)	5 (10%)	2 (20%)
(3) Sale of Schedule 3 poison(s) without the authority of a prescription 在沒有處方授權的情況下出售附表3毒藥	5 (16.13%)	7 (24.13%)	3 (12.5%)	12 (24%)	2 (20%)
(4) Sale of antibiotics without the authority of a prescription 在沒有處方授權的情況下銷售抗生素	0 (0%)	2 (6.9%)	0 (0%)	5 (10%)	1 (10%)
(5) Possession of poison(s) included in Part 1 of the Poisons List 管有毒藥表第1部所列任何毒藥	3 (9.68%)	0 (0%)	1 (4.17%)	0 (0%)	0 (0%)
(6) Possession of unregistered pharmaceutical product(s) 管有未經註冊藥劑製品	0 (0%)	3 (10.34%)	3 (12.5%)	6 (12%)	2 (20%)
(7) Possession for sale or for any purpose of trade or manufacture goods to which a false trade description was applied 為售賣或任何商業或製造用途而管有應用虛假商品說明的貨品	3 (9.68%)	0 (0%)	1 (4.17%)	0 (0%)	0 (0%)
(8) Possession for sale or for any purpose of trade or manufacture goods to which a forged trade mark was applied 為售賣或任何商業或製造用途而管有應用偽造商標的貨品	1 (3.23%)	2 (6.9%)	3 (12.5%)	2 (4%)	1 (10%)
(9) Selling substance(s) to which the Antibiotics Ordinance applies 售賣《抗生素條例》適用的物質	4 (12.9%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
(10) Failing to store poison(s) properly 沒有適當地貯存毒藥	2 (6.45%)	2 (6.9%)	4 (16.66%)	3 (6%)	1 (10%)

Table 表 12 (Con't) 續

Nature of offences* 個案性質*	Number of counts (percentage) 次數 (百份比)				
	2016	2017	2018	2019	2020
(11) Illegal sale of unregistered pharmaceutical product(s) 非法銷售未經註冊的藥劑製品	0 (0%)	0 (0%)	1 (4.17%)	2 (4%)	0 (0%)
(12) Supplying/Offering to supply false trade description goods 供應/要約供應虛假商品説明的貨品	3 (9.68%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
(13) Failing to seek prior approval from the Pharmacy and Poisons Board for change in the ownership/directorship or person-in-charge of the authorized seller of poisons 獲授權毒藥銷售商未事先獲得藥劑業及毒藥管理局的批准，更改了擁有人/董事或負責人	0 (0%)	0 (0%)	0 (0%)	1 (2%)	0 (0%)
(14) Selling goods to which a forged trade mark was applied 出售應用偽造商標的貨品	6 (19.35%)	3 (10.34%)	2 (8.33%)	12 (24%)	1 (10%)
(15) Failing to ensure that all the keys of the lockable receptacle in the dispensing area were kept by the registered pharmacist 未能確保配藥室可上鎖盛器的所有鎖匙由註冊藥劑師保管	0 (0%)	1 (3.45%)	0 (0%)	0 (0%)	0 (0%)
(16) Failing to provide written order(s) in relation to purchasing of controlled medicines 未能提供有關訂購受管制藥物的書面訂單	0 (0%)	1 (3.45%)	0 (0%)	0 (0%)	0 (0%)
(17) Failing to provide sales invoice(s) for controlled medicines 未能提供有關受管制藥物的銷售發票	0 (0%)	1 (3.45%)	0 (0%)	0 (0%)	0 (0%)
(18) Failing to keep proper record of psychotropic substances in psychotropic substances book 未能在精神藥物記錄冊內保存精神藥物有關的妥善記錄	0 (0%)	1 (3.45%)	0 (0%)	0 (0%)	0 (0%)
(19) Trafficking in dangerous drug 販運危險藥物	0 (0%)	0 (0%)	1 (4.17%)	0 (0%)	0 (0%)
(20) Failing to maintain proper record of antibiotics 沒有備存合適的抗生素紀錄	0 (0%)	0 (0%)	0 (0%)	2 (4%)	0 (0%)

* Some cases involve multiple nature of offences
* 部份個案涉及多個罪行

Table 表 12A

Disciplinary Inquiries into Authorized Sellers of Poisons in 2020
2020 年有關獲授權毒藥銷售商的紀律研訊個案



Statistical Tables and Charts
統計圖表

Table 表 13

Number of Listed Sellers of Poisons in Hong Kong
香港的列載毒藥銷售商數目

Year 年份	2016	2017	2018	2019	2020
Number of listed sellers of poisons as at the end of the year 截至年終的列載毒藥銷售商數目	3 937	3 937	3 937	4 295	4 187



Table 表 14

Applications for Licensing as Listed Sellers of Poisons
申請列載毒藥銷售商牌照

Year 年份	2016	2017	2018	2019	2020
Number of applications approved 接納牌照申請數目	231	258	264	624	198
Number of applications rejected 拒絕牌照申請數目	2	0	0	1	0

Statistical Tables and Charts
統計圖表

Table 表 15

Regulatory Control of Listed Sellers of Poisons
列載毒藥銷售商的規管

Year 年份	2016	2017	2018	2019	2020
Number of inspections conducted 巡查數目	7 956	7 874	7 814	8 323	3 268
Number of test purchases conducted 試買數目	4 021	3 229	3 350	3 353	2 144

Note: The numbers of inspections and test purchases in 2020 decreased due to the impact of the COVID-19 pandemic and the social distancing measures.
註： 2020 年的巡查和試買數目受 2019 冠狀病毒病疫情及社交距離措施影響而減少。

Table 表 16

Disciplinary Actions against Listed Sellers of Poisons Taken by the Pharmacy and Poisons Board
藥劑業及毒藥管理局對列載毒藥銷售商採取的紀律行動

Disciplinary actions taken 採取的紀律行動	Number of cases 個案數目				
	2016	2017	2018	2019	2020
Removal from the list of listed sellers of poisons 從列載毒藥銷售商名單除名	4	0	0	1	0
Issue of written warning 發出書面警告	3	4	2	5	2
Suspension of name from the list of listed sellers of poisons for a specified period of time 暫時吊銷名列列載毒藥銷售商名單內的資格一段時間	3	9	4	6	3
The listed seller of poisons ceased operation before action taken by the Board 該銷售商在管理局採取紀律行動前已經結業	0	0	0	0	1
Total 總數	10	13	6	12	6

Statistical Tables and Charts
統計圖表

Table 表 17

Disciplinary Cases regarding Listed Sellers of Poisons Handled by the Pharmacy and Poisons Board
藥劑業及毒藥管理局處理有關列載毒藥銷售商的紀律個案

Nature of offences* 個案性質*	Number of counts (percentage) 次數 (百份比)				
	2016	2017	2018	2019	2020
(1) Sale of Part 1 poison(s) without the supervision of a registered pharmacist/ proper supervision 在沒有註冊藥劑師監督/適當監督的情況下銷售第1部毒藥	4 (10.81%)	1 (3.45%)	1 (8.33%)	2 (7.14%)	2 (15.38%)
(2) Sale of Schedule 3 poison(s) without the authority of a prescription 在沒有處方授權的情況下出售附表3毒藥	3 (8.11%)	1 (3.45%)	0 (0%)	2 (7.14%)	0 (0%)
(3) Possession of Part 1 poison(s) 管有第1部毒藥	6 (16.22%)	8 (27.58%)	4 (33.34%)	3 (10.72%)	2 (15.38%)
(4) Possession of unregistered pharmaceutical product(s) 管有未經註冊藥劑製品	1 (2.70%)	4 (13.79%)	4 (33.34%)	6 (21.43%)	3 (23.10%)
(5) Possession of substance(s) to which the Antibiotics Ordinance applies 管有《抗生素條例》適用的物質	1 (2.70%)	3 (10.34%)	1 (8.33%)	2 (7.14%)	0 (0%)
(6) Possession for sale or for any purpose of trade or manufacture goods to which a forged trade mark was applied 為售賣或任何商業或製造用途而管有應用偽造商標的貨品	8 (21.63%)	1 (3.45%)	0 (0%)	2 (7.14%)	2 (15.38%)
(7) Possession for sale or for any purpose of trade or manufacture goods to which a false trade description was applied 為售賣或任何商業或製造用途而管有應用虛假商品說明的貨品	0 (0%)	1 (3.45%)	0 (0%)	0 (0%)	0 (0%)
(8) Sale of unregistered pharmaceutical product(s) 售賣未經註冊藥劑藥品	0 (0%)	1 (3.45%)	0 (0%)	2 (7.14%)	0 (0%)

Table 表 17(Con't) 續

Nature of offences* 個案性質*	Number of counts (percentage) 次數 (百份比)				
	2016	2017	2018	2019	2020
(9) Selling goods to which a forged trade mark was applied 售賣應用偽造商標的貨品	7 (18.92%)	1 (3.45%)	0 (0%)	4 (14.30%)	4 (30.76%)
(10) Applying a false trade description on goods in the course of any trade or business 在營商過程或業務運作中將虛假商品說明應用於貨品	1 (2.70%)	1 (3.45%)	0 (0%)	1 (3.57%)	0 (0%)
(11) Unlawful sale of Part 2 poison(s) 非法銷售第2部毒藥	4 (10.81%)	4 (13.79%)	0 (0%)	2 (7.14%)	0 (0%)
(12) Illegal use of restricted title 非法使用名銜	1 (2.70%)	0 (0%)	0 (0%)	1 (3.57%)	0 (0%)
(13) Illegal use of restricted logo 非法展示標籤	1 (2.70%)	1 (3.45%)	0 (0%)	1 (3.57%)	0 (0%)
(14) Sale of Part 1 poison(s) 銷售第1部毒藥	0 (0%)	1 (3.45%)	0 (0%)	0 (0%)	0 (0%)
(15) Sale of Schedule 1 Chinese herbal medicine without prescription 沒有按照處方銷售附表1中藥材	0 (0%)	1 (3.45%)	0 (0%)	0 (0%)	0 (0%)
(16) Failing to store poison(s) properly 沒有適當地貯存毒藥	0 (0%)	0 (0%)	1 (8.33%)	0 (0%)	0 (0%)
(17) Engaging in relation to a consumer in a commercial practice that is a misleading omission 就消費者作出屬誤導性遺漏的營業行為	0 (0%)	0 (0%)	1 (8.33%)	0 (0%)	0 (0%)

*Some cases involve multiple nature of offences
*部份個案涉及多個罪行

Table 表 17A

Disciplinary Cases regarding Listed Sellers of Poisons in 2020
2020年有關列載毒藥銷售商的紀律個案



Statistical Tables and Charts
統計圖表

Table 表 18

Issue of Wholesale Dealer Licences
批發商牌照的簽發

Year 年份	2016	2017	2018	2019	2020
Number of holders of wholesale dealer licences as at the end of the year 截至年終的批發商牌照持有人的數目	779	773	770	770	786
Number of wholesale dealer licences revoked/suspended 撤銷或吊銷批發商牌照的數目	1	3	1	2	1

Table 表 19

Issue of Manufacturer's Licences for Pharmaceutical Products
藥劑製品製造商牌照的簽發

Year 年份	2016	2017	2018	2019	2020
Number of holders of manufacturer's licences as at the end of the year 截至年終的製造商牌照持有人的數目	72	72	71	70	69
Number of holders of manufacturer's licences only authorized to conduct secondary packaging of pharmaceutical products as at the end of the year 截至年終只獲授權從事藥劑製品外包裝操作的製造商牌照持有人數目	49	48	48	47	46
Number of manufacturer's licences revoked/suspended 撤銷或吊銷製造商牌照的數目	0	0	0	0	0

Note: With effect from 1 October 2015, all licensed manufacturers were required to fully comply with the PIC/S GMP.

註： 由 2015 年 10 月 1 日起，所有持牌製造商必須完全符合國際醫藥品稽查協約組織的生產質量管理規範指引。

Table 表 20

Number of Registered Authorized Persons
註冊為獲授權人的人數

Year 年份	2016	2017	2018	2019	2020
Number of registered authorized persons for pharmaceutical manufacturers as at the end of the year 截至年終註冊為藥物製造商獲授權人的數目	126	137	145	146	149
Number of registered authorized persons for secondary packaging manufacturers as at the end of the year 截至年終註冊為外包裝製造商的獲授權人數目	83	91	95	95	94
Number of registered authorized persons for pharmaceutical manufacturers of advanced therapy products as at the end of the year 截至年終註冊為先進療法製品製造商的獲授權人數目	N/A 不適用	N/A 不適用	0	0	6
Number of registration of authorized persons cancelled or suspended 取消或暫時吊銷獲授權人註冊的數目	0	0	0	0	0

Note: With effect from 14 September 2018, authorized persons for pharmaceutical manufacturers of advanced therapy products should comply with the requirements set out in the "Guidance on Qualification, Experience and Training Requirements for Authorized Persons and Other Key Personnel of Licensed Manufacturers in Hong Kong" for registration.

註： 由2018年9月14日起，先進療法製品製造商的獲授權人須符合《香港持牌製造商獲授權人及其他關鍵人員的資格、經驗與培訓要求指引》所列的要求方可獲註冊。

Table 表 21

Registration of Pharmaceutical Products
藥劑製品的註冊

Year 年份	2016	2017	2018	2019	2020
Number of registered pharmaceutical products as at the end of the year 截至年終的註冊藥劑製品數目	18 584	18 120	17 323	16 186	15 396



Table 表 22

Amendments to Schedules 1 and 3 to the Pharmacy and Poisons Regulations in 2020
2020年在《藥劑業及毒藥規例》附表1及3作出的修訂

New Substances Added 加入的新物質	
1. Acalabrutinib; its salts	阿可替尼；其鹽類
2. Agalsidase alfa	阿加糖酶α
3. Alpelisib; its salts	阿吡利塞；其鹽類
4. Brolucizumab	布西組單抗
5. Burosumab	布羅索人單抗
6. Capmatinib; its salts	卡馬替尼；其鹽類
7. Carglumic acid; its salts; its esters; their salts	卡谷氨酸；其鹽類；其酯類；它們的鹽類
*8. Codergocrine mesilate	Codergocrine mesilate
9. Crisaborole; its salts	克立硼羅；其鹽類
10. Darolutamide; its salts	達羅他胺；其鹽類
11. Dinutuximab beta	達妥昔單抗β
12. Doravirine; its salts	多拉韋林；其鹽類
13. Entrectinib; its salts	恩曲替尼；其鹽類
14. Erdafitinib; its salts	厄達替尼；其鹽類
15. Galcanezumab	加卡奈組單抗
16. Human cytomegalovirus immunoglobulin	人類巨細胞病毒免疫球蛋白
17. Icatibant; its salts; its esters; their salts	艾替班特；其鹽類；其酯類；它們的鹽類
18. Lemborexant; its salts	萊博雷生；其鹽類
19. Lisdexamfetamine; its salts	利右苯丙胺；其鹽類
20. Lutetium-177; its salts; when contained in pharmaceutical products	鑥-177；其鹽類；但限於包含在藥劑製品
21. Lutetium (177Lu) oxodotreotide; its salts	鑥[177Lu]奧索度曲肽；其鹽類
*22. Metronidazole; its salts; its esters; their salts	甲硝唑；其鹽類；其酯類；它們的鹽類
23. Pegaspargase	培門冬酶
24. Polatuzumab vedotin	維泊妥組單抗
25. Prasterone; its salts; when contained in pharmaceutical products	普拉睪酮；其鹽類；但限於包含在藥劑製品內者
26. Regadenoson; its salts	瑞加諾生；其鹽類
27. Remdesivir; its salts	瑞德西韋；其鹽類

Table 表 22 (Con't) 續

New Substances Added 加入的新物質	
28. Ripretinib; its salts	瑞派替尼；其鹽類
29. Romosozumab	羅莫組單抗
30. Satralizumab	薩特利珠單抗
31. Siponimod; its salts; its esters; their salts	西尼莫德；其鹽類；其酯類；它們的鹽類
32. Sucroferric oxyhydroxide	Sucroferric oxyhydroxide
33. Talazoparib; its salts	他拉唑帕利；其鹽類
34. Tisagenlecleucel	替沙侖賽
#35. Trospium chloride	曲司氯銨
36. Upadacitinib; its salts	烏帕替尼；其鹽類
Others 其他	
1. item "Antisera, antitoxins, immunoglobulins and vaccines", paragraph (b), after sub-item "Rubella" – **Add** "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"	"抗血清、抗毒素、免疫球蛋白與疫苗如下"項目，(b)段，在"霍亂"分項之後 – **加入**"嚴重急性呼吸系統綜合症冠狀病毒2"
2. item "Lovastatin", after "Lovastatin" – **Add** "when contained in pharmaceutical products"	"洛伐他汀"項目，在"洛伐他汀"之後 – **加入**"，但限於包含在藥劑製品內者"
3. item "Pharmaceutical products for human parenteral administration containing the following or their salts, as active ingredients, except in mixture with insulin", after sub-item "Hyoscine" – **Add** "Ibuprofen"	"供注射入人體的藥劑製品，並包含（作為有效成分）以下物質或它們的鹽類，但在與胰島素的混合物內者除外"項目，在"布替他酯"分項之前 – **加入**"布洛芬"
*4. item "Pharmaceutical products for human parenteral administration containing the following or their salts, as active ingredients, except in mixture with insulin" – **Repeal** sub-item "Metronidazole"	"供注射入人體的藥劑製品，並包含（作為有效成分）以下物質或它們的鹽類，但在與胰島素的混合物內者除外"項目 – **廢除**"甲硝唑"分項
5. Chinese text – (a) **Repeal** item "Secukinumab"; (b) **Add** "司庫奇尤單抗"	中文文本 – (a) **廢除** "Secukinumab"項目；(b) **加入**"司庫奇尤單抗"

* These amendments will come into operation on 14 February 2021.
這些修訂自 2021 年 2 月 14 日起實施。

\# These amendments will come into operation on 11 December 2021.
這些修訂自 2021 年 12 月 11 日起實施。

Table 表 23

Amendments to Schedule 10 to the Pharmacy and Poisons Regulations in 2020
2020年在《藥劑業及毒藥規例》附表10作出的修訂

New Substances Added 加入的新物質	
1. Acalabrutinib; its salts	阿可替尼；其鹽類
2. Agalsidase alfa	阿加糖酶α
3. Alpelisib; its salts	阿吡利塞；其鹽類
#4. Azelaic acid	壬二酸
5. Brolucizumab	布西組單抗
6. Burosumab	布羅索人單抗
7. Capmatinib; its salts	卡馬替尼；其鹽類
8. Carglumic acid; its salts; its esters; their salts	卡谷氨酸；其鹽類；其酯類；它們的鹽類
*9. Codergocrine mesilate	Codergocrine mesilate
10. Crisaborole; its salts	克立硼羅；其鹽類
11. Darolutamide; its salts	達羅他胺；其鹽類
12. Dinutuximab beta	達妥昔單抗β
#13. Diprophylline; its salts	二羥丙茶鹼；其鹽類
14. Doravirine; its salts	多拉韋林；其鹽類
15. Entrectinib; its salts	恩曲替尼；其鹽類
16. Erdafitinib; its salts	厄達替尼；其鹽類
17. Galcanezumab	加卡奈組單抗
18. Human cytomegalovirus immunoglobulin	人類巨細胞病毒免疫球蛋白
19. Icatibant; its salts; its esters; their salts	艾替班特；其鹽類；其酯類；它們的鹽類
20. Lemborexant; its salts	萊博雷生；其鹽類
21. Lisdexamfetamine; its salts	利右苯丙胺；其鹽類
22. Lutetium (177Lu) oxodotreotide; its salts	鑥[177Lu]奧索度曲肽；其鹽類
23. Lutetium-177; its salts; when contained in pharmaceutical products	鑥-177；其鹽類；但限於包含在藥劑製品內者
*24. item "Metronidazole; its salts", after "salts" – **Add** "; its esters; their salts"	"甲硝唑；其鹽類"項目，在"其鹽類"之後 – **加入**"；其酯類；它們的鹽類"
25. Pegaspargase	培門冬酶
26. Polatuzumab vedotin	維泊妥組單抗
27. Prasterone; its salts; when contained in pharmaceutical products	普拉睪酮；其鹽類；但限於包含在藥劑製品內者

Table 表 23 (Con't) 續

New Substances Added 加入的新物質	
28. Regadenoson; its salts	瑞加諾生；其鹽類
29. Remdesivir; its salts	瑞德西韋；其鹽類
30. Ripretinib; its salts	瑞派替尼；其鹽類
31. Romosozumab	羅莫組單抗
32. Satralizumab	薩特利珠單抗
33. Siponimod; its salts; its esters; their salts	西尼莫德；其鹽類；其酯類；它們的鹽類
34. Sucroferric oxyhydroxide	Sucroferric oxyhydroxide
35. Talazoparib; its salts	他拉唑帕利；其鹽類
36. Tisagenlecleucel	替沙侖賽
#37. Trospium chloride	曲司氯銨
38. Upadacitinib; its salts	烏帕替尼；其鹽類
Others 其他	
1. item "Antisera, antitoxins, immunoglobulins and vaccines", paragraph (b), after sub-item "Rubella" – **Add** "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"	"抗血清、抗毒素、免疫球蛋白與疫苗如下"項目，(b)段，在"霍亂"分項之後 – **加入**"嚴重急性呼吸系統綜合症冠狀病毒2"
2. item "Lovastatin", after "Lovastatin" – **Add** "when contained in pharmaceutical products"	"洛伐他汀"項目，在"洛伐他汀"之後 – **加入**"，但限於包含在藥劑製品內者"
#3. item "Pharmaceutical products for human parenteral administration containing the following or their salts, as active ingredients, except in mixture with insulin" – **Repeal** sub-item "Diprophylline"	"供注射入人體的藥劑製品，並包含（作為有效成分）以下物質或它們的鹽類，但在與胰島素的混合物內者除外"項目 – **廢除**"二羥丙茶鹼"分項
*4. item "Pharmaceutical products for human parenteral administration containing the following or their salts, as active ingredients, except in mixture with insulin" – **Repeal** sub-item "Metronidazole"	"供注射入人體的藥劑製品，並包含（作為有效成分）以下物質或它們的鹽類，但在與胰島素的混合物內者除外"項目 – **廢除**"甲硝唑"分項
5. Chinese text – (a) **Repeal** item "Secukinumab"; (b) **Add** "司庫奇尤單抗"	中文文本 – (a) **廢除** "Secukinumab"項目；(b) **加入**"司庫奇尤單抗"

Table 表 23 (Con't) 續

Others 其他	
6. Chinese text – (a) item "氰氟蟲腙；其鹽類" (b) item "氰苯哌酸；其鹽類" (c) item "4-氰基-1-甲基-4-苯基哌啶；其鹽類" (d) item "4-氰基-2-二甲胺基-4，4-二苯基丁烷；其鹽類" – **Repeal the items**	中文文本– (a)"氰氟蟲腙；其鹽類"項目 (b)"氰苯哌酸；其鹽類"項目 (c)"4-氰基-1-甲基-4-苯基哌啶；其鹽類"項目 (d)"4-氰基-2-二甲胺基-4，4-二苯基丁烷；其鹽類"項目 – **廢除該等項目**
7. Chinese text – after item "氮芥及二氯乙胺於N位被取代的任何其他衍生物；它們的鹽類" – **Add** "氰氟蟲腙；其鹽類 氰苯哌酸；其鹽類 4-氰基-1-甲基-4-苯基哌啶；其鹽類 4-氰基-2-二甲胺基-4，4-二苯基丁烷；其鹽類"	中文文本 – 在"氮芥及二氯乙胺於N位被取代的任何其他衍生物；它們的鹽類"項目之後 – **加入** "氰氟蟲腙；其鹽類 氰苯哌酸；其鹽類 4-氰基-1-甲基-4-苯基哌啶；其鹽類 4-氰基-2-二甲胺基-4，4-二苯基丁烷；其鹽類"

* These amendments will come into operation on 14 February 2021.
這些修訂自 2021 年 2 月 14 日起實施。

\# These amendments will come into operation on 11 December 2021.
這些修訂自 2021 年 12 月 11 日起實施。


香港藥劑業及毒藥管理局
PHARMACY AND POISONS BOARD OF HONG KONG
PPB